127 related articles for article (PubMed ID: 36152454)
1. Low serum allopregnanolone levels in children with attention deficit hyperactivity disorder.
Şahin İ; Say GN; Avcı B; Kesim N
Psychoneuroendocrinology; 2022 Dec; 146():105923. PubMed ID: 36152454
[TBL] [Abstract][Full Text] [Related]
2. High pretreatment cognitive impulsivity predicts response of oppositional symptoms to methylphenidate in patients with attention-deficit hyperactivity disorder/oppositional defiant disorder.
Golubchik P; Shalev L; Tsamir D; Manor I; Weizman A
Int Clin Psychopharmacol; 2019 May; 34(3):138-142. PubMed ID: 30640748
[TBL] [Abstract][Full Text] [Related]
3. Attention-deficit-hyperactivity disorder with and without oppositional defiant disorder in 3- to 7-year-old children.
Kadesjö C; Hägglöf B; Kadesjö B; Gillberg C
Dev Med Child Neurol; 2003 Oct; 45(10):693-9. PubMed ID: 14515941
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of p300 and spectral resolution in children with attention deficit hyperactivity disorder and specific learning disorder.
Seçen Yazıcı M; Serdengeçti N; Dikmen M; Koyuncu Z; Sandıkçı B; Arslan B; Acar M; Kara E; Tarakçıoğlu MC; Kadak MT
Psychiatry Res Neuroimaging; 2023 Sep; 334():111688. PubMed ID: 37517295
[TBL] [Abstract][Full Text] [Related]
5. [An open trial on effectiveness of parent training in children with comorbid attention deficit hyperactivity disorder and oppositional defiant disorder].
Liu J; Wang YF
Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 39(3):310-4. PubMed ID: 17572790
[TBL] [Abstract][Full Text] [Related]
6. Relationship between anxiety, anxiety sensitivity and conduct disorder symptoms in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Bilgiç A; Türkoğlu S; Ozcan O; Tufan AE; Yılmaz S; Yüksel T
Eur Child Adolesc Psychiatry; 2013 Sep; 22(9):523-32. PubMed ID: 23460041
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
8. The role of tryptophan metabolic pathway in children with attention deficit hyperactivity disorder with and without comorbid oppositional defiant disorder and conduct disorder.
Sağlam E; Bilgiç A; Abuşoğlu S; Ünlü A; Sivrikaya A
Psychiatry Res; 2021 Apr; 298():113770. PubMed ID: 33545424
[TBL] [Abstract][Full Text] [Related]
9. Neurocognitive function in attention-deficit-hyperactivity disorder with and without comorbid disruptive behaviour disorders.
Barnett R; Maruff P; Vance A
Aust N Z J Psychiatry; 2009 Aug; 43(8):722-30. PubMed ID: 19629793
[TBL] [Abstract][Full Text] [Related]
10. Negative outcomes in attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder.
Ayaz AB; Ayaz M; Kayan E
Ir J Psychol Med; 2015 Dec; 32(4):307-312. PubMed ID: 30185252
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
Klassen AF; Miller A; Fine S
Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
[TBL] [Abstract][Full Text] [Related]
12. Impact of Parental Impulsivity on Attention Deficit Hyperactivity Disorder and Oppositional Defiant Disorder: Do Mothers' Attitudes Predict Symptom Severity in Children?
Tulacı ÖD; Çetinkaya M; Tulacı RG; Kara H; Eraslan AN; Durukan I
J Nerv Ment Dis; 2021 Oct; 209(10):759-763. PubMed ID: 34115691
[TBL] [Abstract][Full Text] [Related]
13. Increased attention deficit/hyperactivity and oppositional defiance symptoms of 6-12 years old Chinese children with atopic dermatitis.
Feng LJ; Chen AW; Luo XY; Wang H
Medicine (Baltimore); 2020 Jun; 99(25):e20801. PubMed ID: 32569226
[TBL] [Abstract][Full Text] [Related]
14. Bifactor latent structure of attention-deficit/hyperactivity disorder (ADHD)/oppositional defiant disorder (ODD) symptoms and first-order latent structure of sluggish cognitive tempo symptoms.
Lee S; Burns GL; Beauchaine TP; Becker SP
Psychol Assess; 2016 Aug; 28(8):917-28. PubMed ID: 26502205
[TBL] [Abstract][Full Text] [Related]
15. Differential responses of two related neurosteroids to methylphenidate based on ADHD subtype and the presence of depressive symptomatology.
Molina-Carballo A; Justicia-Martínez F; Moreno-Madrid F; Cubero-Millán I; Machado-Casas I; Moreno-García L; León J; Luna-Del-Castillo JD; Uberos J; Muñoz-Hoyos A
Psychopharmacology (Berl); 2014 Sep; 231(17):3635-45. PubMed ID: 24599397
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of cortisol, dehydroepiandrosterone, and oxytocin in children with attention-deficit/hyperactivity disorder combined presentation with and without comorbid conduct disorder.
Işık Ü; Bilgiç A; Toker A; Kılınç I
Psychiatry Res; 2018 Mar; 261():212-219. PubMed ID: 29324397
[TBL] [Abstract][Full Text] [Related]
17. Does oppositional defiant disorder have temperament and psychopathological profiles independent of attention deficit/hyperactivity disorder?
Kim HW; Cho SC; Kim BN; Kim JW; Shin MS; Yeo JY
Compr Psychiatry; 2010; 51(4):412-8. PubMed ID: 20579516
[TBL] [Abstract][Full Text] [Related]
18. Differences between preschool children with ODD, ADHD, and ODD+ADHD symptoms.
Gadow KD; Nolan EE
J Child Psychol Psychiatry; 2002 Feb; 43(2):191-201. PubMed ID: 11902598
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
